NasdaqGS:VRTXBiotechs
Vertex Pharmaceuticals (VRTX) Profitability Return Tests Bullish Narratives Ahead Of Q1 2026 Earnings
Vertex Pharmaceuticals (VRTX) opened 2026 with Q1 results that build on a solid recent run, following Q4 2025 revenue of US$3.2 billion and basic EPS of US$4.69, supported by trailing 12 month revenue of US$12.0 billion and basic EPS of US$15.46. Over the past few quarters, the company has seen revenue move from US$2.8 billion in Q1 2025 to US$3.2 billion in Q4 2025, while basic EPS shifted from US$2.52 to US$4.69. This points to a business where profitability trends are front and center for...